Cited 51 times in
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이광훈 | - |
dc.contributor.author | 이도연 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김자경 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2014-12-20T16:37:24Z | - |
dc.date.available | 2014-12-20T16:37:24Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/93065 | - |
dc.description.abstract | PURPOSE: Hepatic arterial infusion chemotherapy (HAIC) has often been used as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of HAIC using cisplatin with or without 5-fluorouracil in patients with advanced HCC. METHODS: Between January 2002 and December 2007, we enrolled patients with advanced HCC who underwent HAIC via implantable port systems with cisplatin (60 mg/m(2) on Day 1) with or without 5-fluorouracil (500 mg/m(2) on Days 1-3) every 4 weeks. Tumor response was assessed every two cycles. RESULTS: During follow-up (median 9.5 months), we recorded patient (n = 138) and disease characteristics including median age (53 years), Child-Pugh class A/B (n = 103/35, respectively), portal vein thrombosis (n = 115), and death (n = 121). In total, 561 cycles of HAIC were administered (median four cycles, range 1-14). Ninety-one patients received cisplatin plus 5-fluorouracil, while 47 received only cisplatin. The median progression-free survival (PFS) and overall survival (OS) were 6.0 and 9.5 months, respectively, while the overall disease control rate was 62.3% (3 complete responses, 29 partial responses and 54 stable diseases). Patients treated with cisplatin plus 5-fluorouracil had longer median PFS (7.0 vs. 4.6 months in those given cisplatin only; p = 0.004) and OS (12.0 vs. 7.5 months in those given cisplatin only; p = 0.001). Adverse reactions were tolerable and successfully managed with conservative treatment. CONCLUSIONS: Repetitive HAIC seems well-tolerated and effective in treating advanced HCC, with more therapeutic benefit when treated with cisplatin plus 5-fluorouracil. Future randomized comparative studies are warranted for its efficacy | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 659~667 | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Cisplatin/therapeutic use* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/adverse effects | - |
dc.subject.MESH | Fluorouracil/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infusions, Intra-Arterial | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학) | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Ja Kyung Kim | - |
dc.contributor.googleauthor | Do Youn Lee | - |
dc.contributor.googleauthor | Kwang Hoon Lee | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1007/s00432-010-0917-5 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02676 | - |
dc.contributor.localId | A02718 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00852 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01283 | - |
dc.identifier.eissn | 1432-1335 | - |
dc.identifier.pmid | 20552225 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00432-010-0917-5 | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Hepatic arterial infusion chemotherapy | - |
dc.subject.keyword | 5-fluorouracil | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Prognosis | - |
dc.contributor.alternativeName | Lee, Kwang Hun | - |
dc.contributor.alternativeName | Lee, Do Yun | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Ja Kyung | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Kwang Hun | - |
dc.contributor.affiliatedAuthor | Lee, Do Yun | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Ja Kyung | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 137 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 659 | - |
dc.citation.endPage | 667 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.137(4) : 659-667, 2011 | - |
dc.identifier.rimsid | 28005 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.